Monte Rosa Therapeutics Inc (GLUE)
8.48
-0.15
(-1.74%)
USD |
NASDAQ |
Nov 14, 16:00
8.48
0.00 (0.00%)
After-Hours: 06:22
Monte Rosa Therapeutics Revenue (Quarterly): 4.695M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 4.695M |
Date | Value |
---|---|
March 31, 2024 | 1.064M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.064M
Minimum
Mar 2024
4.695M
Maximum
Jun 2024
2.880M
Average
2.880M
Median
Revenue (Quarterly) Benchmarks
Novartis AG | 13.17B |
MEI Pharma Inc | -- |
Evoke Pharma Inc | 2.654M |
Revance Therapeutics Inc | 59.88M |
Vera Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -30.31M |
Total Expenses (Quarterly) | 37.34M |
EPS Diluted (Quarterly) | -0.43 |
Enterprise Value | 258.24M |
Profit Margin (Quarterly) | -645.6% |
Earnings Yield | -26.42% |